Clinical data for patients with acute myeloid leukemia
| N . | Age (y) . | Sex . | Cytogenetic abnormality . | FAB category . | Source % of blasts . | Response . |
|---|---|---|---|---|---|---|
| 1 | 34 | M | Relapsed M0 | Diploid | PB 93% | Failure |
| 2 | 81 | M | M0 | Diploid | BM 80.4% | CR |
| 3 | 46 | F | M1 relapse | Diploid | PB 95% | CR |
| 4 | 73 | M | Sec M4Eo (RA) | Inv16 | BM 46% | Death during induction |
| 5 | 62 | M | M0 | Diploid | BM 95% | CR |
| 6 | 70 | F | Sec M2 (MDS) | −5, −7, del7 | BM 81.3% | Resistant |
| 7 | 66 | M | Sec AML (CT for leiomyosarcoma) | t(9;11) | BM 89% | CR |
| 8 | 72 | M | Sec M2 (CT for prostate Ca) | Diploid | BM 84% | CR |
| 9 | 72 | M | MDS-AML M4 | Del 5q | BM 65% | No follow-up |
| 10 | 73 | M | Sec M1 (prostate Ca) | Diploid | PB 59% | Primary resistant |
| 11 | 75 | M | M4Eo | Inv16 | BM 40.8% | Failure |
| 12 | 49 | F | M1 relapse | Diploid | BM 90.4% | Primary resistant |
| 13 | 49 | F | Sec M4 (breast Ca) | Diploid | BM 56% | CR |
| 14 | 22 | F | M1 | Iso17Q,10Q | BM 90% | CR |
| 15 | 45 | F | M4 | t(1;16), t(2;3) | BM 64% | CR |
| 16 | 32 | M | 2d relapse M0 | Diploid | BM 70.4% | CR |
| 17 | 75 | M | M4Eos | +8, inv16 | BM 72% | CR |
| 18 | 59 | F | M2 | Diploid | BM 86% | Failure |
| 19 | 82 | M | Sec M1 (MDS) | Diploid | BM 81% | Refused treatment |
| N . | Age (y) . | Sex . | Cytogenetic abnormality . | FAB category . | Source % of blasts . | Response . |
|---|---|---|---|---|---|---|
| 1 | 34 | M | Relapsed M0 | Diploid | PB 93% | Failure |
| 2 | 81 | M | M0 | Diploid | BM 80.4% | CR |
| 3 | 46 | F | M1 relapse | Diploid | PB 95% | CR |
| 4 | 73 | M | Sec M4Eo (RA) | Inv16 | BM 46% | Death during induction |
| 5 | 62 | M | M0 | Diploid | BM 95% | CR |
| 6 | 70 | F | Sec M2 (MDS) | −5, −7, del7 | BM 81.3% | Resistant |
| 7 | 66 | M | Sec AML (CT for leiomyosarcoma) | t(9;11) | BM 89% | CR |
| 8 | 72 | M | Sec M2 (CT for prostate Ca) | Diploid | BM 84% | CR |
| 9 | 72 | M | MDS-AML M4 | Del 5q | BM 65% | No follow-up |
| 10 | 73 | M | Sec M1 (prostate Ca) | Diploid | PB 59% | Primary resistant |
| 11 | 75 | M | M4Eo | Inv16 | BM 40.8% | Failure |
| 12 | 49 | F | M1 relapse | Diploid | BM 90.4% | Primary resistant |
| 13 | 49 | F | Sec M4 (breast Ca) | Diploid | BM 56% | CR |
| 14 | 22 | F | M1 | Iso17Q,10Q | BM 90% | CR |
| 15 | 45 | F | M4 | t(1;16), t(2;3) | BM 64% | CR |
| 16 | 32 | M | 2d relapse M0 | Diploid | BM 70.4% | CR |
| 17 | 75 | M | M4Eos | +8, inv16 | BM 72% | CR |
| 18 | 59 | F | M2 | Diploid | BM 86% | Failure |
| 19 | 82 | M | Sec M1 (MDS) | Diploid | BM 81% | Refused treatment |
FAB, French-American-British classification; PB, peripheral blood; BM, bone marrow; CR, complete remission; sec, secondary; RA, refractory anemia; inv16, inversion 16; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CT, chemotherapy; Ca, carcinoma; del, deletion; iso17q, isochromosome 17q.